Infinity Pharmaceuticals Management Performance

Infinity Pharmaceuticals Inc -- USA Stock  

USD 2.56  0.03  1.16%

Analysis of Infinity Pharmaceuticals manpower and management performance can provide insight into Infinity Pharmaceuticals stock performance. Also an employee sentiment is becoming a valuable factor that investors can use to determine the amount of risk that may be associated with Infinity Pharmaceuticals future performance. Please also check Risk vs Return Analysis.

Infinity Pharmaceuticals Management Effectiveness

The company has return on total asset (ROA) of (27.38) % which means that it has lost $27.38 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (73.91) % meaning that it created substantial loss on money invested by shareholders.

Infinity Pharmaceuticals Insider Trading

Infinity Pharmaceuticals Benchmark Summation

The output start index for this execution was zero with a total number of output elements of seventeen. Infinity Pharmaceuticals Price Series Summation is a cross summation of Infinity Pharmaceuticals price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Infinity Pharmaceuticals Stakeholders

Adelene Perkins Chairman of The Board, CEO and Pres, MBA
Joseph Pearlberg Vice President - Clinical Development, Ph.D
Melissa Hackel Vice President - Finance, MBA
William Bertrand Executive Vice President General Counsel
Lawrence Bloch CFO, Executive Vice President Chief Business Officer, MBA
Julian Adams President of RandD
Sujay Kango Executive Vice President Chief Commercial Officer, MBA
Vito Palombella Chief Scientific Officer and Executive VP
Jeffrey Berkowitz Independent Director
Norman Selby Lead Outside Independent Director, MBA
Jose Baselga Independent Director, Ph.D
Michael Venuti Independent Director, Ph.D
Michael Kauffman Independent Director
Eric Lander Independent Director, Ph.D
David Beier Independent Director
Anthony Evnin Independent Director, Ph.D
Gwendolyn Fyfe Independent Director
Ian Smith Independent Director


Infinity Pharmaceuticals Working Change Over Time

Working Capital

Tenure Analysis

Infinity Pharmaceuticals Employment Tenure
Infinity Pharmaceuticals employes about 56 people. The company is managed by 18 executives with total tenure of roughly 80 years, averanging almost 4.0 years of service per executive having 3.0 employee per reported executive.


Infinity Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.56February 28, 2017
Infinity Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Manpower Efficiency

Return on Infinity Pharmaceuticals Manpower
Revenue Per Employee 578 K
Revenue Per Executive 333.3 K
Net Loss Per Employee 680.3 K
Net Loss Per Executive 3.2 M
Working Capital Per Employee 3.3 M
Working Capital Per Executive 10.3 M

Per Employee

Infinity Pharmaceuticals Per Employee Growth Over Time

Net Income Per Employee

Revenue Per Employee

Number of Employees

Infinity Pharmaceuticals Number of Employees Analysis
Infinity Pharmaceuticals Inc is currently regarded as number one stock in number of employees category among related companies. The total workforce of Pharmaceutical Products industry is currently estimated at about 452. Infinity Pharmaceuticals retains roughly 56.0 in number of employees claiming about 12% of equities listed under Pharmaceutical Products industry.

Earnings Per Share

Infinity Pharmaceuticals Earnings Per Share
According to company disclosure Infinity Pharmaceuticals Inc has Earnings Per Share of -1.14 times. This is 252.0% lower than that of the Healthcare sector, and significantly lower than that of Pharmaceutical Products industry, The Earnings Per Share for all stocks is 149.57% higher than the company.
Earnings per Share is one of the most important measures of the current share price of a firm, and is used by investors to determine the company overall profitability; especially when it is compared to the EPS of similar companies.